Report Details

Biobanks - how to find business trends, R&D, and revenue forecasts

What does the future hold for medical biobanks? Now you get technological and commercial predictions from 2014. Stay ahead, then, for data, helping your authority. There you explore developmental trends, sales results, opportunities, and revenue forecasts.

That new report by visiongain shows you what's possible for biobanking and associated technology to improve healthcare. Avoid missing out. Instead find prospects for that biomedical industry and market, discovering expected trends, progress and gains.

Read on to explore those technologies and services for human medicine, seeing how high revenues can go.

Forecasts and other information showing lucrative possibilities for biorepositories

That study gives you sales predictions to 2024 at overall world, submarket and national level. You also get unit sales predictions. There, for biosample and biospecimen applications, you investigate where demand and money lie.

That way you can avoid struggles to find information. Besides revenue forecasting, our new work shows results, growth rates, and market shares. There you explore those technologies for medical R&D - applications in drug development.

You discover 72 tables, 73 charts, and five interviews with authorities in that industry.

So help your research, analyses, and decisions on storage of human biological samples (HBS). Also benefit your influence.

And the following sections explain what our new investigation gives you.

Forecasting of that world market and its segments - what's likely to happen?

What're the secrets of that industry's progress? Discover in our report overall world revenue to 2024 for storing human cell, tissue and fluid samples, with discussions.

Also find individual revenue predictions to 2024 for nine submarkets at world level:
• Biobanking for research
• Biobanking for therapeutic uses.

That study also forecasts the number of samples stored in those two fields. And it gives biobanking revenue forecasting to 2024 by research application:
• Human tissues (also with sub-forecasts for public sector and commercial uses)
• Stem cells
• Other biological sample banking applications (inc. DNA and body fluids).

And it predicts stem cell banking revenues to 2024 for therapeutic uses:
• Umbilical cord stem cell banking
• Adult stem cell banking.

That study also forecasts the number of stem cell samples banked.

There you assess outlooks for sales expansion, hearing where you could gain. That work investigates competition and demand, showing technological and commercial possibilities.

So discover what's happening. You also assess geographical revenue potentials.

Healthcare in regional markets - what outlooks for biorepository demand and provision?

In developed and developing countries, opportunities for companies providing biobanking facilities, products, services, consumables, and technology will occur from 2014. See where and how.

So our analyses show you individual revenue forecasts to 2024 for 12 national markets:
• United States (US)
• Japan
• Germany, France, UK, Italy, Spain (EU5), and Netherlands
• Brazil, Russia, India, and China (BRIC nations).

There you find countries with highest revenues, demands, and potential growth in usage and sales. Explore progress, needs, opportunities and competitors. And see the gains possible.

Also what events, challenges and advances in technology affect that industry and market? Our work shows you, discussing progress, policies, and trends influencing biorepositories.

Forces affecting developers, producers, and sellers of those medical resources and libraries

The report explains issues, events, and contributions affecting that industry and market from 2014, including these:
• Facilities for cryopreservation, biobank networks, and biobanking infrastructure
• Systems, freezers, operations software, consumables, and services for biobanking
• Guidelines, standards, legislation, regulations, and governmental funding for that biopreservation, inc. HIPAA amendments
• Biobanking in research, drug discovery, and development, inc. biomarkers and personalised medicine
• Uses in therapeutics, clinical trials, and genome-wide association studies (GWAS).

And you explore these influences, among others:
• Umbilical cord blood banking - controversies and possibilities
• Numbers and geographical distribution of biobanks
• Liquid handling systems, frozen aliquotting, and automated DNA isolation
• RFID and tagging technology, and laboratory information management systems (LIMS)
• Biobanking services - storage, management, and transport of biological samples.

So you hear what's happening, also getting feel for challenges, trends, and outlooks.

There you find what stimulates and restrains players in that sector, affecting its results.

Biobanking technologies and applications - top companies and 2018 market value

What happens next? Our study predicts that world market will reach $22.7bn in 2018. In particular, rising demand for biobanked samples for use by pharmaceutical companies in preclinical research stimulates that market.

And in our work you examine activities of many commercial biobanks, including these:
• Tissue Solutions
• Asterand (Stemgent)
• Biopta
• BioServe
• Coriell Institute for Medical Research.

And other companies, including these:
• Cord Blood America
• Cryo-Cell International
• Biogenea Pharmaceuticals
• China Cord Blood Corporation
• ViaCord.

You find 270 organisations covered, exploring competitors. You also get five interviews with leaders in that field. Discover what participants do, say, and think, helping you stay ahead.

Ways Biobanking for Medicine: Technology, Industry and Market 2014-2024 helps

Through knowledge such as this, our new report helps you gain recognition for insight:
• Revenues there to 2024 at world level and for 9 submarkets - assess outlooks for operations, marketing, and sales
• Forecasts to 2024 for 12 national markets in the Americas, Europe, and Asia - investigate developed and developing countries for potential revenues
• Prospects for established organisations, rising companies, and new entrants - explore portfolios, results, strategies, developments, and outlooks for success.

Knowledge there found nowhere else, helping your searches, analyses, and planning

Our report gives independent data. There you get competitive intelligence found only in that work, finding where progress and money lie. You examine the commercial possibilities.

With that original research and analysis you're less likely to fall behind in information or miss opportunity. There see how you could save time and effort. And benefit your plans, decisions, and authority, helping you gain competitive advantages.

Table Of Contents

1. Executive Summary

1.1 What Does This Report Cover?
1.1.1 The Human Tissue Banking Market - Our Definition
1.1.2 The Stem Cell Banking Market - Our Breakdown
1.2 Biobanking for Medicine: Technology, Industry and Market 2014-2024 Overview
1.3 Chapter Outlines
1.4 Speculative Aspects of Assessing the Biobanking Market
1.5 Research and Analysis Methods
1.6 Glossary of Terms in this Report

2. Introduction to Biobanking and its Applications

2.1 What is Biobanking?
2.2 Main Features of Biobanks
2.3 What Processes are Involved in Biobanking?
2.4 Classification of Biobanks: Tissue Type, Volunteer Group and Ownership Classification Models
2.4.1 Volunteer Group: Population- vs. Disease-Based
2.4.2 Ownership Structure: Public vs. Private
2.5 The Guidelines and Standards for Biobanking
2.6 Laws and Regulations for Biobank-Based Research
2.6.1 HIPAA Amendments
2.7 Biobanking and the Pharmaceutical Industry
2.7.1 Biobanking in Research, Drug Discovery and Development
2.7.1.1 Understanding Disease Pathways
2.7.1.2 Drug Discovery
2.7.1.3 Biomarker Discovery in Drug Development
2.7.2 Biobanking for Therapeutics
2.7.3 Biobanking in Clinical Trials

3. Biobanking for Medicine: World Market 2014-2024

3.1 The World Biobanking for Medicine Market in 2013
3.2 Biobanking for Medicine: Research vs. Therapeutics in 2018 and 2024
3.3 World Biobanking for Medicine Market: Overarching Revenue Forecast 2014-2024
3.4 Biobanks Stored Almost 1.3 Billion Specimens in 2013, and That Figure Increases
3.5 The Biobanking for Medicine Market by Sector: Grouped Revenue Forecasts 2014-2024
3.6 Biobanking for Research: A $10bn Industry
3.6.1 Biobanking for Research: Revenue Forecast 2014-2024
3.6.2 Driving Forces Outweigh Restraints on the Biobanking Industry for Research
3.7 Biobanking for Future Therapeutic Use: A Worthwhile Endeavour or a Waste of Money?
3.7.1 Arguments Against Commercial Stem Cell Banking for Therapeutic Purposes
3.7.2 Biobanking for Future Therapeutic Use: Revenue Forecast 2014-2024
3.7.3 Driving and Restraining Forces Influencing the Biobanking Market for Therapeutic Use, 2014-2024

4. Biobanking for Research Purposes

4.1 Breakdown of the Biobanking for Research Market by Tissue Type, 2013
4.2 Biobanking for Research in 2018 and 2024: Comparison by Tissue Type
4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts 2014-2024
4.4 How Many Specimens are Biobanked for Research?
4.5 The Human Tissue Banking Market for Research in 2013
4.6 The Human Tissue Banking Market for Research: Revenue Forecast 2014-2024
4.7 The Human Tissue Banking Market: Commercial vs. Public Sector
4.7.1 Commercial Human Tissue Banks: Revenue Forecast 2014-2024
4.7.2 Public Sector Human Tissue Banks: Revenue Forecast 2014-2024
4.8 The Stem Cell Banking Market for Research in 2013
4.9 The Stem Cell Banking Market for Research: Revenue Forecast 2014-2024
4.9.1 A Shift in RandD Towards Stem Cells
4.10 Banking of Other Biologic Specimens for Research in 2013
4.11 Banking of Other Biologic Specimens for Research: Revenue Forecast 2014-2024

5. Stem Cell Banking for Future Therapeutic Use

5.1 Stem Cell Banking for Therapeutic Use in 2013: A Breakdown by Stem Cell Type
5.2 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenue and Market Share, 2018 and 2024
5.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: A Grouped Revenue Forecast
5.4 How Many Stem Cell Samples Are Biobanked Each Year?
5.5 The Umbilical Cord Blood Banking Market in 2013
5.5.1 Private vs. Public Cord Blood Banking
5.5.2 Umbilical Cord Blood Banking: The Controversies
5.6 The Umbilical Cord Blood Banking Market: Revenue Forecast 2014-2024
5.7 The Adult Stem Cell Banking Market in 2013
5.8 The Adult Stem Cell Banking Market: Revenue Forecast 2014-2024

6. Leading National Markets 2014-2024

6.1 The Geographical Footprint of Biobanking
6.1.1 Biobanking in Europe: Leading the World with Biobanking Networks and Infrastructure
6.1.2 Biobanks in the US: A Fragmented Picture
6.1.3 Biobanking in Asia: A Region Rapidly Gaining Prominence
6.2 Biobanking for Medicine: The US Led the Way in 2013
6.3 The Leading National Markets: A Grouped Revenue Forecast 2014-2024
6.4 How Will Regional Market Shares Change to 2024?
6.5 The US Biobanking Market 2014-2024: Diversifying and Expanding
6.6 The Leading European Biobanking Markets 2014-2024: Leading the Way in Biobanking Infrastructure
6.6.1 Germany: An Advanced Industry with 74 Biobanks Associated with the BBMRI
6.6.2 France: Restrictions on Private Stem Cell Banking Limit the Market
6.6.3 Italy: Is the Limited Private Stem Cell Banking Market Off-Set by Strong Biobanking Networks for Research?
6.6.4 UK: 215 Biobanks Were Licensed Under the HTA in 2013
6.6.5 Spain: Controversy Between Private and Public Umbilical Cord Blood Banks
6.6.6 The Netherlands is Characterised by Comprehensive Biobanking Networks
6.7 The Japanese Biobanking Market 2014-2024: A High Level of Government Investment Drives Growth
6.8 The Biobanking Industry in the BRIC Countries: High Growth and Increasing Market Share Between 2014 and 2024
6.8.1 The Chinese Biobanking Market 2014-2024: The High Rate of Growth Will Continue
6.8.2 The Indian Biobanking Market 2014-2024: Set to Become the Leading Market for Private Stem Cell Banking?
6.8.3 The Brazilian Biobanking Market 2014-2024: Will New Regulations Drive or Restrain the Market?
6.8.4 Russia: Ban on the Import and Export of Human Tissue and Genetic Information Restricts the Market, But Can This Be Overcome from 2014-2024?

7. Technology for Biobanking: Systems, Software, Consumables and Services Associated with Biobanking

7.1 The Biobanking-Associated Market: Overview
7.2 Systems Technology: Fully Automated Handling
7.2.1 Automated Liquid Handling Systems
7.2.2 Frozen Aliquotting: Patented Technology From CryoXtract
7.2.3 Automated DNA Isolation
7.3 Storage Technology: The Most Important Component of Biobanking?
7.3.1 Dry State, Room Temperature Storage Eliminates the Need for Expensive, Energy- Consuming Freezers
7.3.2 Ultra-Low Temperature Freezers: Is Their Use Declining?
7.3.3 Cryopreservation: Mechanical vs. Liquid/ Vapour Phase Nitrogen
7.3.4 Automated Storage and Retrieval Systems: Essential Technology
7.3.5 RFID and Tagging Technology: Advantages over Barcodes
7.4 Software for Biobanks
7.4.1 Laboratory Information Management System (LIMS): Unmet Needs in the Market Remain, Despite Recent Advances
7.4.2 LIMS Functions
7.5 Consumables: High Quality Required for Effective Sample Management
7.5.1 Addressing Sample Storage and Tracking Issues
7.6 Biobanking Services: Storage, Management and Transport of Biologic Samples for a Fee

8. Leading Companies in the Biobanking Market

8.1 The Differing Business Models of Biobanking Companies: Sourcing vs. Storing
8.2 Commercial Biobanks for Research Purposes in 2013
8.2.1 Tissue Solutions: A Virtual Biobank with a Global Presence
8.2.1.1 An Overview of the Products and Services Offered by Tissue Solutions
8.2.1.2 Banked Samples Occur in Many Formats
8.2.1.3 Prospective Tissue Collection for Hard-to-Find Samples
8.2.1.4 Fresh Samples from Surgical Resections are in High Demand
8.2.1.5 Freshly Isolated Human Cells are a Valuable Research Tool
8.2.1.6 FDA/ EMA Panel of Normal Tissues
8.2.1.7 Strengths, Capabilities and the Future Outlook for Tissue Solutions
8.2.2 Asterand is now Part of Stemgent
8.2.2.1 Asterand's Products and Services: XpressBANK, ProCURE and PhaseZERO
8.2.3 Biopta Provides Fresh Human Tissues, for Which Demand is Growing
8.2.3.1 Services From Biopta: Fresh Tissue Sample Procurement and a Variety of Lab Services
8.2.3.2 The First Catalogue of Assays Based on Human Functional Tissues
8.2.3.3 The Future Outlook for Biopta
8.2.4 BioServe: One of the World's Largest Commercial Biorepositories
8.2.4.1 BioServe Offers a Comprehensive List of Services: Biobanking, Sourcing and Preclinical Molecular Services
8.2.4.2 The Future Outlook for BioServe
8.2.5 Coriell Institute for Medical Research: Reportedly the Largest Biobank in the World
8.2.5.1 Features of Coriell Biobank
8.2.5.2 Future Outlook for the Coriell Biobank
8.3 Prominent Biobanks for Therapeutic Use in 2014
8.3.1 Cord Blood America: Expansion into the Emerging Markets Apparently Stalled
8.3.2 Cryo-Cell International: The First Private Cord Blood Bank in the Market
8.3.3 Cryo-Save's Educational Programme Benefits Company's Growth
8.3.4 China Cord Blood Corp: The Only Cord Blood Bank in China with Multiple Licences
8.3.5 LifebankUSA: Placental and Cord Blood Banking Means a Significant Survival Advantage in Transplant Patients
8.3.6 ViaCord: More Blood Units Released for Therapy than Any Other Family Bank
8.3.7 Cord Blood Registry: The World's Largest Newborn Stem Cell Company, Accounting for 3% of the Private Stem Cell Banking Industry
8.3.8 Biogenea Pharmaceuticals: A Comprehensive Offering of Stem Cell Banking Services across the Balkan Peninsula
8.3.9 StemLife is Facing Challenges due to Government Regulations in Malaysia
8.3.10 Future Health Biobank: A Strong Market Presence Owing to International Operations
8.3.11 NeoStem Operates a Multi-Faceted Business Strategy
8.3.12 Precious Cells is Well Positioned to Take Advantage of the Growing Demand in India

9. Qualitative Analysis of the Biobanking Industry and Market 2014-2024

9.1 Industry Trends
9.1.1 The Growing Demand for Biobank Resources for Research
9.1.2 The Establishment of Biobanking Networks
9.1.2.1 BBMRI: The Most Extensive Biobank Network
9.1.3 Virtual Biobanks: Connecting a Fragmented Industry
9.1.4 Commercial Biobanks as Intermediaries: New Resources for Research
9.1.5 Automated Biobanking Has Become Imperative
9.1.6 Increasing Uptake of LIMS
9.1.7 Green Banking - Becoming More Energy Efficient
9.2 The Strengths and Weaknesses of the Biobanking Market in 2014
9.2.1 HBS are Valuable Resources for RandD
9.2.2 Governmental Support for Biobanking Forms a Strength of that Industry
9.2.3 Development of Potential Novel Stem Cell Therapies has Increased Public Awareness of Stem Cell Banking
9.2.4 Insufficient Accessible Numbers of High Quality Biospecimens
9.2.5 Biobanks are Fragmented and Uncoordinated
9.2.6 Lack of Standardisation is a Weakness of the Industry
9.2.7 Lack of Public Awareness Limits Number of Donors
9.2.8 Lack of Engagement with Public Health Services Limits the Stem Cell Banking Market
9.3 Opportunities and Threats Facing the Biobanking Market, 2014-2024
9.3.1 Increasing Use of Biobanked Specimens in Genome-Wide Association Studies (GWAS)
9.3.2 Increasing Demand for Biobanked Samples for Preclinical Research
9.3.3 Biobanking Networks as a Basis for Personalised Medicine
9.3.4 Options for Adult Stem Cell Banking Mean an Increasing Target Population for Private Stem Cell Banks
9.3.5 Even With Governmental Funding, Biobanks Must Become Self-Sufficient to Thrive Long Term
9.3.6 Public Concerns over Confidentiality and Security Threaten Availability of Donors
9.3.7 Limitations Surrounding Informed Consent
9.4 Social, Technological, Economic and Political Factors (STEP) Influencing the Biobanking Industry, 2014-2024

10. Research Interviews from Our Survey

10.1 Interview with Dr Kirstin Goldring, Biobank and BioResource Coordinator, University College London, UK
10.1.1 On the Size of the UCL Biobank and How its Growing
10.1.2 On Users of UCL Biobank
10.1.3 On the Increasing Demand for Biobanked Samples
10.1.4 On Technology Used at UCL Biobank
10.1.5 On the Cost of Access to Samples
10.1.6 Concerns, Challenges and Restraining Factors
10.1.7 The Future of Biobanking
10.2 Interview With Dr Husein Salem, Chief Executive Officer, Precious Cells BioBank, London
10.2.1 On the Increasing Demand for Stem Cell Banking Services
10.2.2 On Novel Stem Cell Therapies in Development
10.2.3 Storage of Adult Stem Cells vs. Storage of Umbilical Cord Blood
10.2.4 On the Demand for Stem Cell Banking in Different Countries
10.2.5 On Challenges in the Industry
10.2.6 On Technology Used at Precious Cells
10.2.7 On Unmet Needs in the Stem Cell Banking Industry
10.2.8 On the Future of Stem Cell Banking
10.3 Interview with Dr David Bunton, CEO and Co-Founder, Biopta Ltd.
10.3.1 One the Use of Human Tissue Samples by Biopharmaceutical Companies
10.3.2 Human Tissue vs. Stem Cells
10.3.3 On the Technology Used in Biobanks
10.3.4 On the Future of the Biobanking Market
10.4 Interview with Dr Michael Leek, Commercial Operations Director, Pharmacells
10.4.1 On the Recent Increase in Stem Cell Banking Activity
10.4.2 On the Services of Pharmacells
10.4.3 On Adult Stem Cell Banking vs. Umbilical Cord Blood Banking
10.4.4 On Challenges Facing the Stem Cell Banking Market
10.4.5 On the Technology Used by Pharmacells
10.4.6 On the Future of the Market
10.5 Interview with Dr Tetsuro Wakatsuki, Chief Scientific Officer, InvivoSciences Inc.
10.5.1 On the Services Provided by InvivoSciences
10.5.2 On the Future of this Biobanking-Associated Market

11. Conclusions from the Research and Analysis

11.1 World Biobanking Market 2014-2024: High Revenue Growth Predicted
11.2 Biobanking for Research 2014-2024: The Value of Biobanked Specimens is Increasingly Recognised
11.3 Biobanking for Therapeutic Use 2014-2024: Rapid Expansion in Adult Stem Cell Banking
11.4 The Leading National Markets: High Sales Growth Worldwide
11.5 Current and Future Trends in Biobanking
11.5.1 Increasing Demand for Biobanked Samples Means Increasing Revenue
11.5.2 Improving Biobanking Infrastructure Engenders Growth
11.5.3 Marked Challenges, but Opportunities for Expansion

List of Tables

Table 1.1 Currency Exchange Rates
Table 2.1 Prominent Population-Based Biobanks, 2014
Table 2.2 Prominent Disease-Based Biobanks, 2014
Table 2.3 Guidelines and Recommendations for Biobanks, 2014
Table 2.4 Laws and Other Regulations for Biobank-Based Research by Country/ Organisation 2014
Table 2.5 Pharmaceutical and Biotechnology Companies with In-House Biobanks, 2014
Table 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Revenue ($bn) and Market Share (%), 2013
Table 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Comparison of Revenues ($bn) and Market Shares (%), 2018 and 2024
Table 3.3 Biobanking for Medicine: Overall World Revenue Forecast ($bn), 2013-2024
Table 3.4 The No. Of Samples Stored in Biobanks by Purpose (m): Forecasts, 2013-2024
Table 3.5 Biobanking for Medicine by Sector: Grouped Revenue Forecasts ($bn), 2013-2024
Table 3.6 Biobanking Market for Research: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 3.7 Biobanking for Therapeutic Use: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 4.1 Biobanking for Research Market by Tissue Type: Revenues ($bn) and Market Shares (%), 2013
Table 4.2 Biobanking for Research by Tissue Type: A Comparison of Revenues ($bn) and Market Shares (%), 2018 and 2024
Table 4.3 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2013-2024
Table 4.4 Number of Research Samples Banked (m): Forecast 2013-2024
Table 4.5 The Human Tissue Banking Market: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 4.6 The Commercial vs. Public Sector Human Tissue Banking Market: Comparison of Revenues ($bn) and Market Shares (%), 2013, 2018 and 2024
Table 4.7 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2013-2024
Table 4.8 Commercial Human Tissue Banking: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 4.9 Prominent Commercial Human Tissue Banks, 2014
Table 4.10 Public Sector Human Tissue Banking: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 4.11 Prominent Public-Funded Human Tissue Banks, 2014
Table 4.12 The Stem Cell Banking Market for Research: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 4.13 Prominent Stem Cell Banks Serving the Research Community, 2014
Table 4.14 Banking of Other Biologic Specimens for Research: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 4.15 Prominent Biobanks Storing Other Biologic Samples, 2014
Table 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Revenues ($bn) and Market Shares (%), 2013
Table 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn) and Market Shares (%), 2018 and 2024
Table 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2013-2024
Table 5.4 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2013-2024
Table 5.5 Prominent Public and Private Cord Blood Banks, 2014
Table 5.6 The Umbilical Cord Banking Market: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 5.7 Prominent Companies in the Adult Stem Cell Banking Industry, 2014
Table 5.8 The Adult Stem Cell Banking Market: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.1 Breakdown of the No. Of Biobanks Associated with BBMRI by Country, 2014
Table 6.2 The Leading National Biobanking Markets: Comparison of Revenues ($bn) and Market Shares (%), 2013
Table 6.3 Leading National Markets: Grouped Revenue Forecasts ($bn) 2013-2024
Table 6.4 The Leading National Markets: Comparison of Market Shares (%), 2014, 2019 and 2024
Table 6.5 Biobanking for Medicine in the US: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.6 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2013-2024
Table 6.7 Examples of Biobanking Initiatives Funded by the European Commission
Table 6.8 The German Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.9 The French Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.10 The Italian Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.11 The UK Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.12 The Spanish Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.13 Prominent Clinical and Population Biobanks in the Netherlands
Table 6.14 The Netherlands Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.15 The Japanese Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.16 The Biobanking Industry in the BRIC Countries: A Grouped Revenue ($bn) and Market Share (%) Forecasts, 2013-2024
Table 6.17 The Chinese Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.18 The Indian Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.19 Prominent Research Biobanks in India, 2014
Table 6.20 The Brazilian Biobanking Market: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 6.21 The Russian Biobanking Industry: Revenue ($bn) and Market Share (%) Forecast, 2013-2024
Table 7.1 Prominent Companies Providing Automated Liquid Handling Technology, 2014
Table 7.2 Prominent Companies Providing Room Temperature Storage Solutions, 2014
Table 7.3 Prominent Companies Providing Ultra-Low Temperature Freezers (-80°C), 2014
Table 7.4 Mechanical Freezing vs. Liquid Nitrogen: Comparison of Advantages and Disadvantages, 2014
Table 7.5 Prominent Companies Providing Cryogenic Storage Solutions, 2014
Table 7.6 Prominent Providers of Automated Biobanking Systems, 2014
Table 7.7 Major Vendors in the LIMS Market, 2014
Table 7.8 Prominent Vendors of Consumables for Biobanking, 2014
Table 7.9 Prominent Biorepository Service Providers, 2014
Table 8.1 Prominent Players in the Biobanking Industry for Research, 2014
Table 8.2 Prominent Companies in the Stem Cell Banking Industry for Therapeutic Use, 2014
Table 8.3 China Cord Blood Corp: Revenue ($m) and No. Of Subscribers, 9 Months Ended Dec. 2012 and 2013
Table 8.4 StemLife: Comparison of Revenue ($m) between 2012 and 2013
Table 9.1 Strengths and Weaknesses of the Biobanking Industry, 2014
Table 9.2 Opportunities and Threats Facing the Biobanking Industry, 2014-2024
Table 9.3 Social, Technological, Economic and Political (STEP) Forces Influencing the Biobanking Industry, 2014-2024

List of Figures

Figure 2.1 Processes Involved in Biobanking, 2014
Figure 2.2 The Classification of Biobanks, 2014
Figure 3.1 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2013
Figure 3.2 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2018
Figure 3.3 Breakdown of the Biobanking Industry by Research vs. Therapeutics: Market Shares (%), 2024
Figure 3.4 Biobanking for Medicine: Overarching Revenue Forecast ($bn), 2013-2024
Figure 3.5 The No. Of Samples Stored in Biobanks by Purpose: Forecasts (m), 2013-2024
Figure 3.6 Biobanking for Medicine by Sector: Grouped Revenue Forecasts ($bn), 2013-2024
Figure 3.7 The Biobanking Market for Research: Revenue Forecast ($bn), 2013-2024
Figure 3.8 Biobanking for Research: Drivers and Restraints, 2014-2024
Figure 3.9 Biobanking for Therapeutic Use: Revenue Forecast ($bn), 2013-2024
Figure 3.10 Biobanking for Therapeutic Use: Drivers and Restraints, 2014-2024
Figure 4.1 The Biobanking for Research Market by Tissue Type: Market Shares (%), 2013
Figure 4.2 Biobanking for Research by Tissue Type: Market Shares (%), 2018
Figure 4.3 Biobanking for Research by Tissue Type: Market Shares (%), 2024
Figure 4.4 Biobanking for Research by Tissue Type: Grouped Revenue Forecasts ($bn), 2013-2024
Figure 4.5 Biobanking for Research: Market Drivers and Restraints, 2014-2024
Figure 4.6 No. Of Research Samples Banked (m): Forecast 2013-2024
Figure 4.7 The Human Tissue Banking Market: Revenue Forecast ($bn), 2013-2024
Figure 4.8 Human Tissue Banking for Research: Market Drivers and Restraints, 2014-2024
Figure 4.9 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2013
Figure 4.10 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2018
Figure 4.11 The Commercial vs. Public Sector Human Tissue Banking Market: Market Shares (%), 2024
Figure 4.12 The Human Tissue Banking Market by Subsector: Revenue Forecasts ($bn), 2013-2024
Figure 4.13 Commercial Human Tissue Banking: Revenue Forecast ($bn), 2013-2024
Figure 4.14 Public Sector Human Tissue Banking: Revenue Forecast ($bn), 2013-2024
Figure 4.15 The Stem Cell Banking Market for Research: Revenue Forecast ($bn), 2013-2024
Figure 4.16 Stem Cell Banking for Research: Market Drivers and Restraints, 2014-2024
Figure 4.17 Banking of Other Biologic Specimens for Research: Revenue Forecast ($bn), 2013-2024
Figure 4.18 Biobanking of Other Biologic Specimens for Research: Market Drivers and Restraints, 2014-2024
Figure 5.1 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2013
Figure 5.2 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2018
Figure 5.3 Biobanking for Therapeutic Use by Stem Cell Type: Market Shares (%), 2024
Figure 5.4 Biobanking for Therapeutic Use by Stem Cell Type: Grouped Revenue Forecasts ($bn), 2013-2024
Figure 5.5 The Number of Stem Cell Samples Banked for Therapeutic Use (m): Forecast 2013-2024
Figure 5.6 The Stem Cell Banking Market for Future Therapeutic Use: Drivers and Restraints, 2014-2024
Figure 5.7 The Umbilical Cord Banking Market: Revenue Forecast ($bn), 2013-2024
Figure 5.8 The Umbilical Cord Blood Banking Market: Drivers and Restraints, 2014-2024
Figure 5.9 The Adult Stem Cell Banking Market: Revenue Forecast ($bn), 2013-2024
Figure 5.10 The Adult Stem Cell Banking Market: Drivers and Restraints, 2014-2024
Figure 6.1 The Leading National Biobanking Markets: Market Shares (%), 2013
Figure 6.2 The Leading National Markets: A Grouped Revenue Forecasts ($bn), 2013-2024
Figure 6.3 The Leading National Markets: Market Shares (%), 2014
Figure 6.4 The Leading National Markets: Market Shares (%), 2019
Figure 6.5 The Leading National Markets: Market Shares (%), 2024
Figure 6.6 Biobanking for Medicine in the US: Revenue Forecast ($bn), 2013-2024
Figure 6.7 Driving and Restraining Factors of the US Biobanking Market, 2014-2024
Figure 6.8 The Leading European Markets for Biobanking: Grouped Revenue Forecasts ($bn), 2013-2024
Figure 6.9 Biobanking in the Leading European Countries: Driving and Restraining Factors, 2014-2024
Figure 6.10 The German Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.11 The French Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.12 The Italian Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.13 The UK Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.14 The Spanish Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.15 The Netherlands Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.16 The Japanese Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.17 Driving and Restraining Factors Influencing the Japanese Biobanking Industry, 2014-2024
Figure 6.18 The Biobanking Industry in the BRIC Countries: Grouped Revenue Forecasts ($bn), 2013-2024
Figure 6.19 Driving and Restraining Factors of the Biobanking Industry in the BRIC Countries, 2014-2024
Figure 6.20 The Chinese Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 6.21 The Indian Biobanking Industry: Revenue ($bn) Forecast, 2013-2024
Figure 6.22 The Brazilian Biobanking Market: Revenue Forecast ($bn), 2013-2024
Figure 6.23 The Russian Biobanking Industry: Revenue Forecast ($bn), 2013-2024
Figure 7.1 Structure of the Biobanking Industry: Biobanking-Associated Market, Biobanks and End Users, 2014
Figure 7.2 The Basic Function of LIMS
Figure 8.1 Biobanking Business Model: Commercial Sourcing of Biological Samples, 2014
Figure 8.2 Business Model: Commercial Banking of Biological Samples, 2014
Figure 8.3 China Cord Blood Corp: Revenue ($m) and No. Of Subscribers, 9 Months Ended Dec. 2012 and 2013
Figure 8.4 StemLife: Comparison of Revenue ($m), 2012 and 2013
Figure 11.1 The Global Biobanking Market by Industry Sector: Comparison of Revenues ($bn), 2014, 2019 and 2024
Figure 11.2 Biobanking for Research by Sample Type: Comparison of Revenues ($bn), 2014, 2019 and 2024
Figure 11.3 Stem Cell Banking for Therapeutic Use by Stem Cell Type: Comparison of Revenues ($bn), 2014, 2019 and 2024
Figure 11.4 The Leading Regional Markets for Biobanking: Comparison of Revenues ($bn), 2014, 2019 and 2024

Companies Listed

Abbott Laboratories
Accelrys
Adnexus Therapeutics
Advanced Innovative Medicine
AIS
AKH Biobank
AllCells
Allied Minds
AlloSource
American CryoStem
American Type Culture Collection
Amgen
Analytical Biological Services
ARUP Laboratories
ASPREE Healthy Aging Biobank
AssureImmune
Asterand
AstraZeneca
Aurora Biomed
Australasian Biospecimen Network
Autoscribe Informatics
AuxoCell Laboratories
AXM Shenyang
Bangalore Brain Bank
Barts Gynae Tissue Bank
Bayer
Beckman Coulter
Beijing Children's Hospital Biobank
BINDER
Biobank Ireland
Biobank Japan
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
BioCells
BioFortis
Biogen Idec
Biogenea
BioLife Solutions
Biomatrica
Biomedical Research Council (BMRC)
Biopta
BioRep
BioRepository Resources
Bioseek
BioServe Biotechnologies
BioSHARE-EU
BioStorage Technologies
Biovault Technical
Bluechiip
BrainNet Europe
Bristol-Myers Squibb
Brooks Life Science Systems
Cambridge Biomedical Research Centre
Cambridge Bioscience
Canadian Partnership for Tomorrow
Cancer Human Biobank (caHUB)
CCLG Tissue Bank
Celgene
Cellectis
Cells4Life
Celltex Therapeutics
Cellular Dynamics
Chernobyl Tissue Bank
China Cord Blood Corp.
China Kadoorie Biobank
China Stem Cells
CLB/ Amsterdam Medical Center
CMD Biobank
CONCOR
CorCell Companies
Cord Blood Registry
CordBlood America
CordLife
CordVida
CORE Informatics
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Creative Bioarray
Cryo Bio System
Cryo Save
Cryo-Cell International
Cryogene Lab
CryoLogic
Cryopraxiz
Cryo-Save
CryoXtract
Cureline
Custom Biogenic Systems
Cybrdi
Daifuku
deCODE Genetics
Deloitte
Department of Health
Eli Lilly
Eppendorf
Esco
ESFRI
European Commission (EC)
European Health Risk Monitoring (EHRM)
European Medicines Agency (EMA)
European Union Group on Ethics (EGE)
European, Middle-Eastern and African Society for Biopreservation and Biobanking (ESBB)
Fisher BioServices
Flinders Technology Associates (FTA)
FluidX
Food and Drug Administration (US FDA)
Future Health Biobank
GC Biotech
GE Healthcare
GE Healthcare SeqWright Genomic Services
Genentech
Genome Quebec Biobank
GenVault
Gilson
Glasgow Caledonian University
GlaxoSmithKline (GSK)
H. Lee Moffitt Cancer Center and Research Institute
Hamilton Robotics
Hamilton Storage Technologies
Harvard Stem Cell Institute
Harvard University
Hospital Necker Paris
HTA (Human Tissue Authority)
Hudson Robotics
Human Science Research Resource Bank (HSRRB)
Human Tissue Bank
Hungarian Biobank
Huntington Disease Biobank
Idivumed
ILSBio
Imperial Tissue Bank
Inbiomed
Indian Institute of Technology
Indivumed
Infectious Disease Biobank
INSERM
IntegenX
International Agency for Research on Cancer (IARC)
International Air Transport Association (IATA)
International Organization for Standardization (ISO)
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
InvivoSciences
Japan Health Sciences Foundation
Kaiser Permanente
King's College London Tissue Bank
Labtech
LabVantage
Labware
Leiden Longevity
Leiden University Medical Center
LifeBank USA
LifeCell
LifeGene
LifeLines Biobank
Malmö Microbiology Biobank
MatriCal Bioscience
Medical College of Wisconsin
Medical Research Council
Medivision
Merck and Co.
Merck-Serono
Micronic
Ministry of Health and Welfare
Mitochondrial Disease Biobank
Narayana Hrudayalaya Tissue Bank and Stem Cell Research Center
National Biological Resource Centre (Centro Nazionale per le Risorse Biologiche - CNRB)
National Cancer Institute (NCI)
National Institute of Health (NIH)
NeoStem
NESDA
Netherlands Twin Registry
NHS Blood and Transplant Cord Blood Bank
Northeastern University
Northwest Regional Development Agency
Novare Biologistics
Novartis
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
Pacific BioStorage
PALGA
Panasonic Biomedical
Parelsnoer
Perkin Elmer
Pfizer
Pharmacells
Pop-Gen National Cohort
Precious Cells
Precision Bioservices
PrecisionMed
PREVEND
Progenicyte
Progenitor Cell Therapy (PCT)
ProMedDx
Promega
ProteoGenex
Provia Labs
Qiagen
RAND
Riken BRC Cell Bank
Roche
Rotterdam Study
RTS Life Sciences
Russian Ministry of Health
Russian Society for Biobanking and Biopreservation (RSBB)
Russian Society of Personalised Medicine (RSPM)
Saneron CCEL Therapeutics
Sanofi
Sapien Biosciences
Sceil
Seattle Genetics
Sechenov First Moscow Medical University (SFMMU)
Sepax
Sigma Aldrich
Singapore Biobank (SBB)
Singapore Cord Blood Bank
Singapore Tissue Network (STN)
Smart Cel

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

Global Next-generation Sequencing Trends

Global Next-generation Sequencing Trends

  • $ 12 500
  • Industry report
  • September 2014
  • by Frost & Sullivan

An End-user Perspective The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house ...

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

Single Nucleotide Polymorphism (SNP) Genotyping: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report discusses market growth, size and opportunities with respect to applications, geographic region and technologies. Forecast trends and revenue are given through 2019. Major players, ...

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

MicroRNA Research Tools, Diagnostics and Therapeutics: Global Markets

  • $ 6 650
  • Industry report
  • September 2014
  • by BCC Research

This BCC Research report provides an overview of the current state of the microRNA (miRNA) market, focusing mainly on continuing research endeavors, newly emerging sophisticated tools, reagents, techniques, ...

Global Bioinformatics Industry

July 2014 $ 4 950

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.